The Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee voted on May 11 to recommend an epinephrine nasal spray product for the treatment of severe allergic reactions, including anaphylaxis. The 22-member advisory committee voted 16–6 to recommend approval of the 2 ...